It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...

Robert F. Kennedy Jr.'s nomination for US health secretary advances with crucial Republican support, despite controversy over ...